anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Obesity is a well established risk factor for type 2 diabetes mellitus, hypertension, dyslipidemia and cardiovascular disease. Along with rapid nutritional and lifestyle transition featured as increased energy dense diet intake and reduced physical activity, the prevalence of obesity has reached epidemic level and affected more than 70 million Chinese adults nowadays. Previous studies suggested that low-carbohydrate diet was an effective and safe way to lose weight and had potential benefit on lipids profiles. However, it is still unknown whether this diet can be feasible to control the epidemic of obesity and its related metabolic diseases among Chinese, whose carbohydrate consumption contribute approximately 55% of total energy intake.

Therefore, the aim of this pilot study is to investigate the adherence and effectiveness of two weight-loss diets among Chinese. This will be a randomized, controlled clinical trial. A total of 50 overweight or obese nurse assistants will be randomly assigned to receive a low-carbohydrate diet or a traditional high-carbohydrate Chinese but restricted-calories diet for 12 weeks. The adherence of study protocol and effects of the two diets on body weight, waist circumference, body fat, fasting glucose and lipid profile will be evaluated.
BACKGROUND: Opioids are irreplaceable analgesics owing to the lack of alternative analgesics that offer opioid-like pain relief. However, opioids have many undesirable central side effects. Restricting opioids to peripheral opioid receptors could reduce those effects while maintaining analgesia.
METHODS: To achieve this goal, we developed Tet1-LNP (morphine), a neural-targeting lipid nanoparticle encapsulating morphine that could specifically activate the peripheral opioid receptor in the dorsal root ganglion (DRG) and significantly reduce the side effects caused by the activation of opioid receptors in the brain. Tet1-LNP (morphine) were successfully prepared using the thin-film hydration method. In vitro, Tet1-LNP (morphine) uptake was assessed in differentiated neuron-like PC-12 cells and dorsal root ganglion (DRG) primary cells. The uptake of Tet1-LNP (morphine) in the DRGs and the brain was assessed in vivo. Von Frey filament and Hargreaves tests were used to assess the antinociception of Tet1-LNP (morphine) in the chronic constriction injury (CCI) neuropathic pain model. Morphine concentration in blood and brain were evaluated using ELISA.
RESULTS: Tet1-LNP (morphine) had an average size of 131 nm. Tet1-LNP (morphine) showed high cellular uptake and targeted DRG in vitro. CCI mice treated with Tet1-LNP (morphine) experienced prolonged analgesia for nearly 32 h compared with 3 h with free morphine (p < 0.0001). Notably, the brain morphine concentration in the Tet1-LNP (morphine) group was eight-fold lower than that in the morphine group (p < 0.0001).
CONCLUSION: Our study presents a targeted lipid nanoparticle system for peripheral neural delivery of morphine. We anticipate Tet1-LNP (morphine) will offer a safe formulation for chronic neuropathic pain treatment, and promise further development for clinical applications.
Azithromycin is a macrolide antibiotic used for treating infections. This is available in a solid oral dosage form. It is desirable to have a clear liquid formulaiton also for treating severe infections by intravenous administration of the drug. Currently, it is not possible to manufacture liquid preparation which is ready to use. As it is not soluble in water or other known solvents, for this purpose, it is being marketed as lyophilized preparation which is reconstituted prior to use. According to present invention, it is found that it is soluble in water at pH 5.0. The change in pH can be obtained by adding citric acid in a desired concentration. However, this solution is not stable, and precipitates are seen over the time. According to the present invention, this solution is stabilized by addition of sodium salts like sodium hydroxide, thereby changing its pH from 5.0 to 7.0. The solution so prepared remains clear and is stable for a longer period.
Red Blood Cell Labeling Procedure

  1. Labeling may be performed without washing or centrifugation steps directly in the reaction vial.
  2. A 30 to 50 mL sample of whole blood is withdrawn from the patient and added aseptically to a vial of ACD Solution Modified.
  3. 50 to 150 microcuries of Sodium Chromate 51 is then injected into the reaction vial using a shielded syringe. The amount of radioactivity added to the vial will

depend on the intended use of the labeled red blood cells.

  4. The suspension is incubated for 30 to 60 minutes at room temperature with frequent, gentle agitation.
  5. After incubation, 100 mg Ascorbic Acid Injection is injected into the vial. The ascorbic acid reduces any remaining unbound dianionic chromium 51 to the anionic state which does not penetrate red blood cells; thus in vivo labeling of red blood cells is prevented.
The invention discloses a PH-sensitive konjac glucomannan material for reducing weight in stomach and a preparation method thereof. The PH sensitive gastric weight loss material is in a compressed sponge structure, and the shape and the size of the product are similar to those of common medicines. The preparation method comprises the following steps: dissolving konjac glucomannan solution, adding a certain amount of croscarmellose sodium into the solution, quickly stirring to uniformly mix the solution, and freeze-drying. The obtained sponge is crushed, the crushed sponge and the cross-linked PVP are uniformly mixed, and the mixture is compressed to the size of a capsule after being humidified at high temperature. Finally, the mixture is filled into capsules, and the product is prepared after packaging and sterilization. The product also comprises a stomach pH regulator, which mainly comprises magnesium aluminum carbonate, sodium carboxymethyl cellulose and the like. The PH-sensitive glucomannan gastric weight loss material has the advantages of stable structure, strong liquid absorption capacity, relatively simple and convenient manufacturing process, high repeatability and high product safety, and can be widely applied to the field of medical appliances.
A medicinal substance for increasing fertility in mammalian males and for use as an anti-microbial or anti-inflammatory agent by mammals produced by boiling radish leaves, radish stems or portions thereof in water for a period of time sufficient to produce a tea containing an extract from the radish leaves and stems or portions thereof. Alternatively, the radish leaves and stems may be placed in hot water for a period of time sufficient to produce a tea containing the extract. The resulting tea can be drunk hot or cold and may be stored in a refrigerator for extended periods of time for later use. Patients taking a daily dosage of this tea have shown greatly improved sperm density and improved motility and morphology after use for several weeks. Dosages of this tea are also effective in treating prostatitis. The preferred radish plant is the spring radish of the species Raphanus sativus. The leaves of other radish plants including wild and winter or oriental radishes may also be used.
The invention relates to a traditional Chinese medicine preparation for treating leg pain after sports doing and a preparation method thereof. The traditional Chinese medicine preparation is prepared from the following traditional Chinese medicine raw materials: lycopodium clavatum, garden balsam stems, radix clematidis, wild yellow roots, radix et rhizoma rhei, raw myrrh, sapanwood, safflowers, notopterygium roots, radix sileris, rhizoma ligustici wallichii, herba menthae, angelica sinensis roots, curcuma zedoary, mulberry fruit, herba hedyotidis diffusae, folium isatidis, silkworm larva, fructus bruceae, raw coix seeds, honeysuckle stems, Tribulus terrestris, Chinese violets, rhizoma alismatis and fiveleaf akebia. The traditional Chinese medicine preparation is pasted in the pain position of the leg part; the massage is used in a matched way, so that the effect is better. The skin in the pasting position is required to be complete without a wound; if the wound exists, the wound needs to be subjected to bundling and isolation treatment, then, the traditional Chinese medicine preparation can be used. The traditional Chinese medicine preparation provided by the invention has the effects of promoting qi and blood circulation, stopping arthralgia spasm pain, cooling the blood, eliminating scars, promoting blood circulation and dredging collaterals; through the nerve and body fluid regulating effect, the blood circulation condition of the pain position is improved; the metabolism is promoted; the adsorption of blood stasis and edema is accelerated. The side effect is very low; the external application is used, so that excited medicine is prevented from entering the body; the condition of self reputation influence due to misuse of exhilarants by athletes is avoided.
Participants will receive JNJ-63709178 in Part 1 (in different cohorts). Each subsequent cohort will receive JNJ-63709178 at an increased dose level. Ascending doses may be given initially to minimize or prevent cytokine release syndrome. Dose escalation will continue until the maximum tolerated dose is reached or all planned doses are administered.
In August 2021, two juvenile male Antarctic fur seals (Arctocephalus gazella) stranded in the southeastern Brazilian coast and were referred to rehabilitation centers. The animals presented increased body temperature, prostration, respiratory distress and despite treatment died. A necropsy following a standardized protocol was performed, and formalin-fixed tissues were processed for microscopic examination. Samples were screened for morbillivirus, herpesvirus, and Brucella spp. by molecular analyses (PCR, RT-PCR). Bacteriological culture was performed in samples collected from the lungs, trachea, and lymph nodes of both cases. The main histopathologic findings were of infectious nature, including multifocal necrotizing and fibrinous mixed interstitial pneumonia, bronchiolitis, and bronchitis, with intralesional myriad bacteria associated with vascular fibrinoid necrosis. Pseudomonas aeruginosa was isolated from tracheal and lung swabs of Case 1, and Klebsiella oxytoca was found in nostril swabs, tracheobronchial lymph nodes, and lung of Case 2. Gammaherpesvirus infection was detected in both cases, and the sequences retrieved were classified into the genus Percavirus. All tested samples were PCR-negative for Brucella spp. and morbillivirus. We hypothesize that the deficient immunological status in association with starvation predisposed the reactivation of herpesvirus and secondary bacterial co-infections. To the authors' knowledge, this is the first molecular detection of herpesvirus in an Antarctic pinniped. These findings reinforce that Otariid gammaherpesvirus circulating in the Southern Hemisphere are likely endemic in the Arctocephalus genus. This report contributes to the current knowledge of health aspects affecting wild pinnipeds, especially in the poorly studied Antarctic species.
Within the scope of Nursing Fundamentals course, a 4-hour theoretical training will be given to the experimental group in the classroom setting. Video presentation including powerpoint presentation and tracheostomy care skill application will be prepared in line with the Respiratory System course content. The powerpoint presentation prepared will be explained by the researchers to the video group students in the classroom by question, answer, discussion and demonstration methods. Immediately after the lecture, students will be watched by the video-assisted teaching method, and the video of tracheostomy care The videos will be sent to students via e-mail. A two-day warning message will be sent to the students from the WhatsApp group to watch the video by the researchers. A week later, students will be invited to the basic skills laboratory for tracheostomy care.
The pharmaceutical form is a tablet or capsule containinggranules, spheroids or pellets (multiparticles). It includes from10 to 500 mg morphine or its pharmaceutically acceptable salt anda carrier controlling the release. The morphine or itspharmaceutically acceptable salt have from 10 to 60 wt.%. Thespeed of releasing the actively effecting substance ensures peakplasma level from 1 to 6 h after the application, and the plasmalevels are maintained in such a way that the pain is eased for 24hrs. The pharmaceutical form is also characterized by parameterW50 determining the period of time during which the plasmaconcentration is equal or higher than 50% of the peak plasmaconcentration for the morphine, as well as by characteristics ofrelease in vitro. The method includes mechanical treatment ofpowder active substance and hydrophobic meltable carrier orthinner having melting temperatures from 35 to 150oC, and,optionally, an additional component for controlling the release.The treatment is conducted with speed and supplied energy enablingthe carrier or the thinner to be molten and form agglomerates.21 claims, 7 figures
A drug infusion system 110 for manually controlled infusion of a drug into a patient. System 110 comprises a user guidance device 112 for informing a required change to a pump volume displacement parameter of a manual drug infusion pump. User-guidance device 112 includes: a pump-volume displacement parameter measurement component 124; and a computer which: calculates a measured rate of patient drug infusion using the measured pump-volume-displacement parameter; with reference to the measured infusion rate and at least one model selected from a group of pharmacokinetic and pharmacodynamic models, calculates a model-simulated patient drug concentration; and derives and outputs user-guidance information based upon the model-simulated drug concentration. Preferably, system 110 further includes a manual drug infusion pump 120 preferably selected from syringes and non-pharmacokinetic, zero-order syringe-pumps combined with syringes. The computer may use the pump volume displacement parameter and the model in calculating a rate of infusion required for achieving a patient drug concentration within a target concentration range. System 110 may comprise a plurality of infusion-pumps 120 and measurement-components 124 for simultaneously infusing a plurality of drugs. Also, a computer-method for informing required changes to pump-volume-displacement-parameters. Applications include performing anaesthesia or sedation with intravenous anaesthetic agents.
Flotation-REST (reduced environmental stimulation therapy) alters the balance of sensory input by systematically attenuating signals from the visual, auditory, thermal, tactile, vestibular, and proprioceptive systems. Previous research has shown that this heightens interoceptive awareness and reduces anxiety in clinically anxious populations. Anorexia nervosa (AN) is characterized by elevated anxiety, distorted body image, and disrupted interoception, raising the question of whether floatation therapy might positively impact these symptoms. A recent safety study found that Floatation-REST was well tolerated by individuals weight-restored outpatients with current or prior AN. Additionally, participants reported improvements in affective state and body image disturbance following floating, raising the possibility that this intervention might be investigated for clinical benefit in more acutely ill cases.

The primary aim of this study is to begin to examine the effect of Floatation-REST on body image disturbance in inpatients with AN. Secondary aims including determining whether Floatation-REST has an impact on anxiety, emotional distress, eating disorder severity, functional ability, and interoception.
OBJECTIVES: Descending necrotizing mediastinitis (DNM) developing after deep neck infection (DNI) is a potentially lethal disease of the mediastinum with a mortality rate as high as 40% prior to the 1990s. No standard treatment protocol is available. Here, we present the outcomes of our multidisciplinary approaches for treating DNM originating from a DNI.
METHODS: Between June 2016 and July 2021, there were 390 patients with DNIs admitting to our tertiary hospital. A total 21 patients with DNIs complicated with DNM were enrolled. The multidisciplinary approaches included establishment of airway security, appropriate surgery and antibiotics, extracorporeal membrane oxygenation, and intensive care unit management. The clinical variables were analyzed.
RESULTS: Two patients died and 19 survived (mortality 9.5%). The patients who died had a higher mean C-reactive protein (CRP) level than did those who survived (420.0 ± 110.3 vs 221.8 ± 100.6 mg/L) (P = .038). The most common pathogens were Streptococcus constellatus and Streptococcus anginosus. From 2001 to 2021, the average mortality rate of studies enrolling more than 10 patients was 16.1%.
CONCLUSION: Multidisciplinary approaches, early comprehensive medical treatment, and co-ordination among departments significantly reduce mortality. Patients with severe inflammation and high CRP levels require intensive and aggressive interventions.
Placebo IV plus docetaxel (75 mg/m²) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
This is a double blinded cross-over randomized controlled trial study conducted on all the patients of the dental clinic indicated for bilateral extraction or filling.

The randomization method is block balanced randomization. All patients will ask to fulfill the ethical Form. This form acquired demographic information (e.g. age, sex) about patients. A panoramic radiograph will take from those who matched the inclusion criteria and signed the agreement. Then a tooth from one side will be treated and the tooth from the other side of the mouth will treat at least 2 weeks later by the same dentist.
BACKGROUND: Spinach downy mildew, caused by the obligate oomycete pathogen, Peronospora effusa remains a major concern for spinach production. Disease control is predominantly based on development of resistant spinach cultivars. However, new races and novel isolates of the pathogen continue to emerge and overcome cultivar resistance. Currently there are 20 known races of P. effusa. Here we characterized the transcriptomes of spinach, Spinacia oleracea, and P. effusa during disease progression using the spinach cultivar Viroflay, the near isogenic lines NIL1 and NIL3, and P. effusa races, R13 and R19, at 24 h post inoculation and 6 days post inoculation. A total of 54 samples were collected and subjected to sequencing and transcriptomic analysis.
RESULTS: Differentially expressed gene (DEG) analysis in resistant spinach interactions of R13-NIL1 and R19-NIL3 revealed spinach DEGs from protein kinase-like and P-loop containing families, which have roles in plant defense. The homologous plant defense genes included but were not limited to, receptor-like protein kinases (Spiol0281C06495, Spiol06Chr21559 and Spiol06Chr24027), a BAK1 homolog (Spiol0223C05961), genes with leucine rich repeat motifs (Spiol04Chr08771, Spiol04Chr01972, Spiol05Chr26812, Spiol04Chr11049, Spiol0084S08137, Spiol03Chr20299) and ABC-transporters (Spiol02Chr28975, Spiol06Chr22112, Spiol06Chr03998 and Spiol04Chr09723). Additionally, analysis of the expression of eight homologous to previously reported downy mildew resistance genes revealed that some are differentially expressed during resistant reactions but not during susceptible reactions. Examination of P. effusa gene expression during infection of susceptible cultivars identified expressed genes present in R19 or R13 including predicted RxLR and Crinkler effector genes that may be responsible for race-specific virulence on NIL1 or NIL3 spinach hosts, respectively.
CONCLUSIONS: These findings deliver foundational insight to gene expression in both spinach and P. effusa during susceptible and resistant interactions and provide a library of candidate genes for further exploration and functional analysis. Such resources will be beneficial to spinach breeding efforts for disease resistance in addition to better understanding the virulence mechanisms of this obligate pathogen.
The problem is stated in the following starting questions:

What conditions and factors are associated with infection and non-infection by SARS-CoV-2 among health professionals working in the three hospitals on the islands of Santiago and São Vicente? Which are they (gender, age group, profession, type of contact, etc.)? Where do the infected HCW typically work (sector)? When and how did the infection occur? What is the prevalence of SARS-CoV-2 antibody in professionals with confirmed SARS-CoV-2 infection and in HCW that thought they were not infected by SARS-CoV-2? How long do anti-SARS-CoV-2 antibodies last? What is the impact of infection on unplanned absenteeism? Which symptoms and complaints (if any) persists after SARS-CoV-2 infection?
This randomized controlled trial will include patients diagnosed with plantar fasciitis. Participants will be randomly assigned to either a study group performing gastrocnemius stretches or a control group. Both groups will receive ultrasound therapy and fascia strengthening exercises. The study group will additionally perform specific gastrocnemius stretching exercises. Outcome measures will be assessed before and after 4 weeks of intervention and will include pain intensity, foot mobility using an inversion/eversion device, and function using the Foot and Ankle Ability Measure. The study hypothesizes that the study group will demonstrate greater improvements in pain, foot mobility, and function compared to the control group. The study findings could guide physical therapy interventions for patients with plantar fasciitis.
Peripheral blood mononuclear cells (PBMC) for the generation of ATC will be collected using 1 or 2 phereses to obtain 8-20 × 109 PBMC for T cell expansion. The PBMC will be activated with OKT3 and expanded in IL-2 to generate from 20-320 ×109 ATC during a maximum of 14 days of culture. Three patients will be treated at each dose level. The dose levels for each infusion are: 5, 10, 20, and 40 billion. Each patient will receive a total of 8 doses of armed ATC given twice weekly for 4 weeks. If the patients encounter toxicities related to armed ATC, the dose and administration will be modified as delineated per the protocol. The patients will also receive subcutaneous injections of IL-2 (3.0 × 105 IU/m2/day) starting 3 days before the 1st armed ATC infusion and ending 7 days after the last armed ATC infusion. GM-CSF (250μg/m2 twice per week) will given subcutaneously to start 3 days before the 1st armed ATC infusion and ending 7 days after the last dose of armed ATC.